Abstract
Breast cancer relapse and death occur more often and sooner among young pre-menopausal women. Breast cancer resected during luteal phase cures about a quarter more women than if the operation is performed during follicular phase. We have identified candidate breast cancer gene signatures that may point to the potential mechanisms of cycle stage-dependent surgical cure. We performed whole murine genome microarrays on mammary tumors resected during pre-ovulatory (diestrus, follicular) and post-ovulatory (estrus, luteal) phases of the estrous cycle with known post-surgical cure or relapse (pulmonary metastasis) outcome. A set of genes whose expressions are differentially modulated by fertility cycle stage of tumor resection and also associate with prognosis were identified. These identified genes were validated by qRT-PCR. From two independent microarray studies, we identified 90 genes in mammary tumors whose expressions change significantly (up to 100-fold) across the estrous cycle, 69 genes that are associated with cure/relapse independent of cycle stage at resection, and 24 genes that change significantly (up to 12-fold) across the estrous cycle and also associate with the outcome. The mRNA expression patterns of these 24 identified genes were 100% validated by qRT-PCR in the same samples. We have identified candidate breast cancer genes and pathways that may point to the potential mechanisms by which the post-resection breast cancer outcome is influenced by the menstrual cycle phase of cancer resection. Since human breast cancer outcome is influenced by the menstrual cycle phase of breast cancer resection, we consider this study in a mouse breast cancer model to be a proof of principle that such signatures may well exist in human premenopausal breast cancer. It remains to be determined in human breast cancer whether woman to woman and/or tumor to tumor variability will mask cycle phase dependent and outcome predictive genomic signatures in human premenopausal breast cancer. The pathways identified by these studies are potential targets for the development of peri-surgical neoadjuvant therapies, which may delay or prevent relapse by preventing dormant micrometastatic tumor cells from escaping that dormant state post-operatively.
Similar content being viewed by others
References
SEER Surveillance, Epidemiology, and End Results (SEER) Program (2007) Limited-Use Data (1973–2004) (www.seer.cancer.gov), National Cancer Institute, DCCPS, surveillance research program, cancer statistics branch, released April 2007, based on the November 2006 submission
Demicheli R et al (2007) Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nat Clin Pract Oncol 4(12):699–710. doi:10.1038/ncponc0999
Baum M et al (2005) Does surgery unfavourably perturb the “natural history” of early breast cancer by accelerating the appearance of distant metastases? Eur J Cancer 41(4):508–515. doi:10.1016/j.ejca.2004.09.031
Kleinfeld G, Haagensen CD, Cooley E (1963) Age and menstrual status as prognostic factors in carcinoma of the breast. Ann Surg 157:600–605. doi:10.1097/00000658-196304000-00016
Cooper AP (1836) In: Lee A (ed) Practice and principles of surgery. E. Cox, London
Beatson GT (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2:104–107. doi:10.1016/S0140-6736(01)72307-0
Hrushesky WJM et al (1989) Menstrual influence on surgical cure of breast cancer. Lancet 334(8869):949–952. doi:10.1016/S0140-6736(89)90956-2
Powles TJ et al (1991) Timing of surgery in breast cancer. Lancet 337:164. doi:10.1016/0140-6736(91)90816-8
Senie R et al (1991) Timing of breast cancer excision during the menstrual cycle influences duration of disease-free survival. Ann Intern Med 115:337–342
Meyer K (1991) Season and cycle: variation in presentation and response to therapy in premenopausal breast cancer. In proceedings of the 77th annual clinical congress, Chicago, October 21–24
Ville V et al (1991) Timing of surgery in breast cancer. Lancet 337:1604–1605. doi:10.1016/0140-6736(91)92223-O
Spratt J, Zirnheld J, Yancey J (1993) Breast cancer detection demonstration project data can determine whether the prognosis of breast cancer is affected by the time of surgery during the menstrual cycle. J Surg Oncol 53:4–9. doi:10.1002/jso.2930530104
Marques L, Franco E (1993) Association between timing of surgery during menstrual cycle and prognosis in pre-menopausal breast cancer. Int J Cancer 53:707–708. doi:10.1002/ijc.2910530430
Badwe R, Wang D, Gregory W (1994) Serum progesterone at the time of surgery and survival in woman with premenopausal operable breast cancer. Eur J Cancer 30A:445–448. doi:10.1016/0959-8049(94)90415-4
Saad Z et al (1994) Timing of surgery in relation to the menstrual cycle in premenopausal women with operable breast cancer. Br J Surg 81:217–220. doi:10.1002/bjs.1800810219
Veronesi U et al (1994) Effect of menstrual phase of surgical treatment of breast cancer. Lancet 343:1545–1547. doi:10.1016/S0140-6736(94)92942-4
Harlap S et al (1998) Survival of premenopausal women with breast carcinoma: effects of menstrual timing of surgery. Cancer 83(1):76–88. doi:10.1002/(SICI)1097-0142(19980701)83:1<76∷AID-CNCR11>3.0.CO;2-9
Stonelake P, Powell J, Dunn J (1995) Influence of timing of surgery during menstrual cycle on survival of premenopausal woman with operable breast cancer. Breast 4:19–24. doi:10.1016/0960-9776(95)90023-3
Love RR et al (2002) Mastectomy and oophorectomy by menstrual cycle phase in women with operable breast cancer. J Natl Cancer Inst 94:662–669
Hagen A, Hrushesky W (1998) Menstrual timing of breast cancer surgery. Am J Surg 104:245–261. doi:10.1016/S0002-9610(97)00294-8
Fentiman IS, Gregory WM, Richards MA (1994) Effects of menstrual phase on surgical treatment of breast cancer. Lancet 344:402. doi:10.1016/S0140-6736(94)91428-1
Demicheli R et al (2007) Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nat Clin Pract Oncol 4(12):699–710. doi:10.1038/ncponc0999
Lundy J et al (1979) Immune impairment and metastatic tumor growth: the need for an immunorestorative drug as an adjunct to surgery. Cancer 43(3):945–951. doi:10.1002/1097-0142(197903)43:3<945::AID-CNCR2820430324>3.0.CO;2-V
Romsdahl MM (1964) Influence of surgical procedures on development of spontaneous lung metastases. J Surg Res 4:363–370. doi:10.1016/S0022-4804(64)80085-8
Fisher B, Fisher ER (1959) Experimental evidence in support of the dormant tumor cell. Science 130:918–919. doi:10.1126/science.130.3380.918
Jones FS, Rous P (1914) On the cause of the localization of secondary tumors at points of injury. J Exp Med 20:404–412. doi:10.1084/jem.20.4.404
Hrushesky WJM (1996) Breast cancer, timing of surgery, and the menstrual cycle: call for prospective trial. J Womens Health 5(6):555–565
van ‘t Veer LJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536. doi:10.1038/415530a
Liu R et al (2007) The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356(3):217–226. doi:10.1056/NEJMoa063994
van de Vijver MJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999–2009. doi:10.1056/NEJMoa021967
Wang Y et al (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365(9460):671–679
Tan BK et al (2008) Clinical validation of a customized multiple signature microarray for breast cancer. Clin Cancer Res 14(2):461–469. doi:10.1158/1078-0432.CCR-07-0999
Feng YM et al (2006) Identification of the differentially expressed genes between primary breast cancer and paired lymph node metastasis through combining mRNA differential display and gene microarray. Zhonghua Yi Xue Za Zhi 86(39):2749–2755
Frasor J et al (2006) Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res 66(14):7334–7340. doi:10.1158/0008-5472.CAN-05-4269
Nuyten DS et al (2006) Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 8(5):R62. doi:10.1186/bcr1614
Paik S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24(23):3726–3734. doi:10.1200/JCO.2005.04.7985
Ikeda T, Jinno H, Shirane M (2007) Chemosensitivity-related genes of breast cancer detected by DNA microarray. Anticancer Res 27(4C):2649–2655
Modlich O, Prisack HB, Bojar H (2006) Breast cancer expression profiling: the impact of microarray testing on clinical decision making. Expert Opin Pharmacother 7(15):2069–2078. doi:10.1517/14656566.7.15.2069
Reid JF et al (2005) Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst 97(12):927–930
Bove K et al (2002) Fertility cycle influence on surgical breast cancer cure. Breast Cancer Res Treat 75(1):65–72. doi:10.1023/A:1016543222323
Ratajczak HV, Sothern RB, Hrushesky WJ (1988) Estrous influence on surgical cure of a mouse breast cancer. J Exp Med 168(1):73–83. doi:10.1084/jem.168.1.73
Weng L et al (2006) Rosetta error model for gene expression analysis. Bioinformatics 22(9):1111–1121. doi:10.1093/bioinformatics/btl045
Mylonas I et al (2007) Steroid receptors ERalpha, ERbeta, PR-A and PR-B are differentially expressed in normal and atrophic human endometrium. Histol Histopathol 22(2):169–176
Silberstein GB et al (2006) Estrogen-triggered delays in mammary gland gene expression during the estrous cycle: evidence for a novel timing system. J Endocrinol 190(2):225–239. doi:10.1677/joe.1.06725
Mote PA et al (2006) Overlapping and distinct expression of progesterone receptors A and B in mouse uterus and mammary gland during the estrous cycle. Endocrinology 147(12):5503–5512. doi:10.1210/en.2006-0040
Mustanoja SM et al (1999) Evidence against alpha2-adrenoceptor involvement in the regulation of rat melatonin synthesis by ambient lighting. Neuroscience 92(3):967–973. doi:10.1016/S0306-4522(99)00057-3
Mustanoja SM et al (1999) Supersensitivity with reduced capacity for pineal melatonin synthesis in constant light-treated rats. J Neural Transm 106(7–8):645–655. doi:10.1007/s007020050186
Boyd M, Hildebrandt R, Bristow S (1996) Expression of the estrogen receptor gene in developing and adult human breast. Breast Cancer Res Treat 37:243–251. doi:10.1007/BF01806506
Soderqvist G et al (1993) Estrogen and progesterone receptor content in breast epithelial cells from healthy women during the menstrual cycle. Am J Obstet Gynecol 168(3 Pt 1):874–879
Kreitmann B, Bugat R, Bayard F (1979) Estrogen and progestin regulation of the progesterone receptor concentration in human endometrium. J Clin Endocrinol Metab 49(6):926–929
Song RX et al (2007) Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. Endocrinology 148(8):4091–4101. doi:10.1210/en.2007-0240
Curtis CD et al (2007) Interaction of the tumor metastasis suppressor nonmetastatic protein 23 homologue H1 and estrogen receptor alpha alters estrogen-responsive gene expression. Cancer Res 67(21):10600–10607. doi:10.1158/0008-5472.CAN-07-0055
Planas-Silva MD, Waltz PK (2007) Estrogen promotes reversible epithelial-to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 104(1–2):11–21. doi:10.1016/j.jsbmb.2006.09.039
Banka CL et al (2006) Estrogen induces lung metastasis through a host compartment-specific response. Cancer Res 66(7):3667–3672. doi:10.1158/0008-5472.CAN-05-4416
Wood PA et al (2005) Cancer growth and spread are saltatory and phase-locked to the reproductive cycle through mediators of angiogenesis. Mol Cancer Ther 4(7):1065–1075. doi:10.1158/1535-7163.MCT-05-0028
Hyder SM et al (2000) Regulation of vascular endothelial growth factor expression by estrogens and progestins. Environ Health Perspect 108(Suppl 5):785–790. doi:10.2307/3454307
Saad Z et al (1998) Expression of genes that contribute to proliferative and metastatic ability in breast cancer resected during various menstrual phases. Lancet 351:1170–1173. doi:10.1016/S0140-6736(97)07498-9
Wood PA, Hrushesky WJM (2005) Sex cycle modulates cancer growth. Breast Cancer Res Treat 91(1):95–102. doi:10.1007/s10549-005-8269-6
Nicholson SE et al (2005) Suppressor of cytokine signaling (SOCS)-5 is a potential negative regulator of epidermal growth factor signaling. Proc Natl Acad Sci USA 102(7):2328–2333. doi:10.1073/pnas.0409675102
Zhang JG et al (1999) The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci USA 96(5):2071–2076. doi:10.1073/pnas.96.5.2071
Magrangeas F et al (2000) Cloning and expression of CIS6, chromosome assignment to 3p22 and 2p21 by in situ hybridization. Cytogenet Cell Genet 88(1–2):78–81. doi:10.1159/000015490
Kile BT et al (2002) The SOCS box: a tale of destruction and degradation. Trends Biochem Sci 27(5):235–241. doi:10.1016/S0968-0004(02)02085-6
Lin L et al (2001) Detection of differentially expressed genes in mouse lung adenocarcinomas. Exp Lung Res 27(3):217–229. doi:10.1080/019021401300053966
Tobita H et al (2006) Gene expression profile of DNA binding protein A transgenic mice. Int J Oncol 29(3):673–679
Suomela S et al (2004) Interferon alpha-inducible protein 27 (IFI27) is upregulated in psoriatic skin and certain epithelial cancers. J Invest Dermatol 122(3):717–721. doi:10.1111/j.0022-202X.2004.22322.x
Wild PJ et al (2005) Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res 11(12):4415–4429. doi:10.1158/1078-0432.CCR-05-0259
Ayers SD et al (2007) Continuous nucleocytoplasmic shuttling underlies transcriptional activation of PPARgamma by FABP4. Biochemistry 46(23):6744–6752. doi:10.1021/bi700047a
Kaporis HG et al (2007) Human basal cell carcinoma is associated with Foxp3+ T cells in a Th2 dominant microenvironment. J Invest Dermatol 127(10):2391–2398. doi:10.1038/sj.jid.5700884
Christa L et al (1994) Overexpression of glutamine synthetase in human primary liver cancer. Gastroenterology 106(5):1312–1320
Baglietto L et al (2007) Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 16(4):763–768. doi:10.1158/1055-9965.EPI-06-0960
Maor S et al (2007) Insulin-like growth factor-I controls BRCA1 gene expression through activation of transcription factor Sp1. Horm Metab Res 39(3):179–185. doi:10.1055/s-2007-970415
Schaffer A et al (2007) Insulin-like growth factor-I and risk of high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 16(4):716–722. doi:10.1158/1055-9965.EPI-06-0924
Subramanian A et al (2007) Evidence for a tumour suppressive function of IGF1-binding proteins in human breast cancer. Anticancer Res 27(5B):3513–3518
Vizoso F et al (2001) Lysozyme expression by breast carcinomas, correlation with clinicopathologic parameters, and prognostic significance. Ann Surg Oncol 8(8):667–674. doi:10.1007/s10434-001-0667-3
Dennis JL et al (2005) Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 11(10):3766–3772. doi:10.1158/1078-0432.CCR-04-2236
Tappel A (2005) Lysosomal enzymes and initiation of breast cancer. Med Hypotheses 64(2):288–289. doi:10.1016/j.mehy.2004.07.025
Grandin N, Charbonneau M (2007) Mrc1, a non-essential DNA replication protein, is required for telomere end protection following loss of capping by Cdc13, Yku or telomerase. Mol Genet Genomics 277(6):685–699. doi:10.1007/s00438-007-0218-0
Lukashova-v Zangen I et al (2007) Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival. Acta Neuropathol 113(3):325–337. doi:10.1007/s00401-006-0190-5
Breedlove HA et al (2006) Serum selenium measurements in women with early-stage breast cancer with and without chemotherapy-induced ovarian failure. Breast Cancer Res Treat 97(3):225–230. doi:10.1007/s10549-005-9012-z
Yajima S et al (2007) Expression profiling of fecal colonocytes for RNA-based screening of colorectal cancer. Int J Oncol 31(5):1029–1037
Racila E et al (2006) The pattern of clinical breast cancer metastasis correlates with a single nucleotide polymorphism in the C1qA component of complement. Immunogenetics 58(1):1–8. doi:10.1007/s00251-005-0077-y
Liu CJ et al (2006) Array-comparative genomic hybridization to detect genomewide changes in microdissected primary and metastatic oral squamous cell carcinomas. Mol Carcinog 45(10):721–731. doi:10.1002/mc.20213
Thomassen M, Tan Q, Kruse TA (2008) Gene expression meta-analysis identifies chromosomal regions and candidate genes involved in breast cancer metastasis. Breast Cancer Res Treat. doi:10.1007/s10549-008-0038-x
Sasaki H et al (2001) Expression of Periostin, homologous with an insect cell adhesion molecule, as a prognostic marker in non-small cell lung cancers. Jpn J Cancer Res 92(8):869–873
Bao S et al (2004) Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 5(4):329–339. doi:10.1016/S1535-6108(04)00081-9
Shao R et al (2004) Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol Cell Biol 24(9):3992–4003. doi:10.1128/MCB.24.9.3992-4003.2004
Furuya M et al (2004) Expression of regulator of G protein signalling protein 5 (RGS5) in the tumour vasculature of human renal cell carcinoma. J Pathol 203(1):551–558. doi:10.1002/path.1543
Berger M et al (2005) Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization. Blood 105(3):1094–1101. doi:10.1182/blood-2004-06-2315
Boss CN et al (2007) Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen. Clin Cancer Res 13(11):3347–3355. doi:10.1158/1078-0432.CCR-06-2156
Han Lee ED et al (2003) Approaches toward reversal of increased vascular permeability in C1 inhibitor deficient mice. Immunol Lett 89(2–3):155–160. doi:10.1016/S0165-2478(03)00130-5
Davis AEIII (2004) Biological effects of C1 inhibitor. Drug News Perspect 17(7):439–446. doi:10.1358/dnp.2004.17.7.863703
Li D, Bachinski LL, Roberts R (2001) Genomic organization and isoform-specific tissue expression of human NAPOR (CUGBP2) as a candidate gene for familial arrhythmogenic right ventricular dysplasia. Genomics 74(3):396–401. doi:10.1006/geno.2001.6558
Mukhopadhyay D et al (2003) CUGBP2 plays a critical role in apoptosis of breast cancer cells in response to genotoxic injury. Ann N Y Acad Sci 1010:504–509. doi:10.1196/annals.1299.093
Seimiya M et al (2003) Stage-specific expression of Clast6/E3/LAPTM5 during B cell differentiation: elevated expression in human B lymphomas. Int J Oncol 22(2):301–304
Cheon YP et al (2004) Induction of cytotoxic T-lymphocyte antigen-2beta, a cysteine protease inhibitor in decidua: a potential regulator of embryo implantation. J Biol Chem 279(11):10357–10363. doi:10.1074/jbc.M309434200
Ghosh A et al (2004) Crystal structure of IIGP1: a paradigm for interferon-inducible p47 resistance GTPases. Mol Cell 15(5):727–739. doi:10.1016/j.molcel.2004.07.017
Pawitan Y et al (2005) False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics 21(13):3017–3024. doi:10.1093/bioinformatics/bti448
Acknowledgments
These studies were supported in part by VA Merit Award (WJMH and PAW), National Institutes of Health grants R01 CA31635 and RO1 CA50749 (WJMH).
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Oh, EY., Wood, P.A., Yang, X. et al. Discovery of candidate genes and pathways that may help explain fertility cycle stage dependent post-resection breast cancer outcome. Breast Cancer Res Treat 118, 345–359 (2009). https://doi.org/10.1007/s10549-008-0253-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-008-0253-5